The urgent need for efficacious drugs to treat chronic hepatitis C virus (HCV) infection requires a concerted effort to develop inhibitors specific for virally encoded enzymes. We demonstrate that 2-C-methyl ribonucleosides are efficient chain-terminating inhibitors of HCV genome replication. Characterization of drug-resistant HCV replicons defined a single S282T mutation within the active site of the viral polymerase that conferred loss of sensitivity to structurally related compounds in both replicon and isolated polymerase assays. Biochemical analyses demonstrated that resistance at the level of the enzyme results from a combination of reduced affinity of the mutant polymerase for the drug and an increased ability to extend the incorporated nucleoside analog. Importantly, the combination of these agents with interferon-␣ results in synergistic inhibition of HCV genome replication in cell culture. Furthermore, 2-C-methyl-substituted ribonucleosides also inhibited replication of genetically related viruses such as bovine diarrhea virus, yellow fever, and West African Nile viruses. These observations, together with the finding that 2-C-methyl-guanosine in particular has a favorable pharmacological profile, suggest that this class of compounds may have broad utility in the treatment of HCV and other flavivirus infections.
The urgent need for efficacious drugs to treat chronic hepatitis C virus (HCV) infection requires a concerted effort to develop inhibitors specific for virally encoded enzymes. We demonstrate that 2-C-methyl ribonucleosides are efficient chain-terminating inhibitors of HCV genome replication. Characterization of drug-resistant HCV replicons defined a single S282T mutation within the active site of the viral polymerase that conferred loss of sensitivity to structurally related compounds in both replicon and isolated polymerase assays. Biochemical analyses demonstrated that resistance at the level of the enzyme results from a combination of reduced affinity of the mutant polymerase for the drug and an increased ability to extend the incorporated nucleoside analog. Importantly, the combination of these agents with interferon-␣ results in synergistic inhibition of HCV genome replication in cell culture. Furthermore, 2-C-methyl-substituted ribonucleosides also inhibited replication of genetically related viruses such as bovine diarrhea virus, yellow fever, and West African Nile viruses. These observations, together with the finding that 2-C-methyl-guanosine in particular has a favorable pharmacological profile, suggest that this class of compounds may have broad utility in the treatment of HCV and other flavivirus infections.
Hepatitis C virus (HCV)
1 is the most common blood-borne infection and a major cause of chronic liver disease and liver transplantation in industrialized countries. The prevalence of HCV infection is estimated to be ϳ5-fold greater than HIV infection and ranges from 1-5% in most developed countries (1) . Current therapy is both poorly tolerated and has limited efficacy, with less than 50% response rates among patients infected with the most prevalent virus genotype (1b) (1) . Currently approved drugs for the treatment of hepatitis C are interferon-␣ and ribavirin, neither of which appears to act directly on the virus, and their antiviral effects appear to be mediated by multiple, indirect mechanisms. Therefore, there is a need for more efficient and better tolerated anti-HCV agents.
The success of antiviral therapies based on chemotherapeutic agents targeting viral polymerases has prompted intense efforts to develop inhibitors of HCV NS5B, the virally encoded RNA-dependent RNA polymerase (RdRp). Studies with HIV reverse transcriptase validate the clinical utility of two distinct classes of viral polymerase inhibitors, nucleoside and non-nucleoside inhibitors. Nucleoside inhibitors function as competitive substrate analogs that prevent RNA chain elongation when incorporated by the viral enzyme, resulting in premature chain termination (2, 3) . HIV reverse transcriptase non-nucleoside inhibitors bind to a site residing outside the enzyme active site and inhibit catalysis by an allosteric mechanism (4, 5) . Several putative allosteric binding sites on the surface of HCV NS5B have been suggested based on recent structural studies (6 -8) , and several chemical classes of NS5B non-nucleoside inhibitors have been described (7) (8) (9) . Although these compounds inhibit both purified HCV NS5B and viral replication using the cell-based replicon system, their mechanism of action has not yet been genetically validated and therefore it remains to be demonstrated that they possess direct antiviral activity. We recently reported the identification of two nucleoside inhibitors, 2Ј-C-methyl-adenosine (2Ј-C-Me-A) and 2Ј-Omethyl-cytidine (2Ј-O-Me-C), that inhibit HCV replication in a cell-based replicon assay, and their corresponding triphosphates inhibit NS5B activity (10) . Here, we report genetic data demonstrating that inhibition of HCV replication by 2Ј-modified nucleosides in cell culture is due to direct NS5B inhibition and present evidence suggesting that members of this compound class might have clinical utility against a broad spectrum of related positive strand viruses.
EXPERIMENTAL PROCEDURES
Selection of Drug-resistant Replicons-Parental Huh-7 and the replicon harboring cells HBI10A were cultured as described (11) . Clones resistant to 2Ј-C-Me-A were selected as described previously (11) .
Briefly, HBI10A cells were plated in 15-cm tissue culture dishes at a density of 3 ϫ 10 3 /cm 2 and cultured in the presence of 0.8 mg/ml G418 and 2Ј-C-Me-A at concentrations increasing from 1 to 5 M. Approximately 15 days after beginning of selection, small colonies of cells resistant to the inhibitor and the antibiotic became visible and were isolated. The sequence of HCV replicons present in drug-resistant cell clones was obtained following extraction of replicon RNA from resistant cell clones, reverse transcriptase PCR, and direct sequencing of PCR products (11) .
HCV Replicon Assays-An in situ RNase protection assay that measures viral RNA with a riboprobe complementary to HCV NS5B was used to measure the effect of inhibitors on viral genome replication. Conditions for the in situ RNase protection assays were as described previously (10) . Transient genome replication assays were performed by transfection of replicons harboring the NS5A S232I adaptive mutation that expressed the ␤-lactamase reporter, and replication was measured by quantitation ␤-lactamase reporter activity as described previously (12) . The S282T mutation was introduced by site-directed mutagenesis using standard techniques. Transfected cells were cultured in the absence of drug for 4 days and in the presence of inhibitor compound for 48 h prior to reading. IC 50 determinations were calculated as a percent of the Me 2 SO control by fitting the data to a 4-parameter fit function using Kaleidagraph software (Synergy Software, Reading, PA).
NS5B Enzyme Assays-HCV (genotype 1b) NS5B⌬55 was expressed in Escherichia coli and purified as described previously (13) . K m for ATP and k cat values were determined from a nonlinear least square fit of initial rates as a function of substrate concentration assuming Michaelis-Menten kinetics. Assays were performed with 10 nM wild type (WT) NS5B⌬55 or 25 nM S282T mutant enzyme and 40 nM heteropolymeric RNA template (22) in 20 mM Tris-HCl (pH 7.5), 0.05% Triton X-100, 2% glycerol, 50 mM NaCl, 1 mM dithiothreitol, 0.1 g/l bovine serum albumin, 0.25 units/l RNasin, and 5 mM MgCl 2 . The NS5B protein was preincubated with template RNA for 15 min at room temperature, and elongation reaction was started by the addition of 100 M UTP, CTP, and GTP and increasing amounts of ATP and [␣-32 P]ATP (0.06 Ci/M cold ATP). Elongation was allowed to proceed for 5 min at 37°C, and the activity was measured as the radioactivity present in the acid-insoluble material. Under these conditions, reaction rates at the highest concentration of ATP approached saturation. IC 50 values were determined in NS5B-catalyzed reactions that included 25 nM wild type NS5B⌬55 or 90 nM S282T NS5B⌬55 in a 50-l reaction containing 90 nM template t500 (13), 20 mM Tris (pH 7.5), 80 mM KCl, 2 mM MgCl 2 , 5 mM dithiothreitol, 0.4 unit/l rRNasin (Promega, Madison, WI), 0.2% polyethylene glycol-8000, 50 M EDTA, 1 M NTPs (unless otherwise noted), and ϳ 0.2-0.5 Ci of either [␣-
33 P]GTP or -ATP (PerkinElmer Life Sciences). Reactions were initiated by the addition of a mixture of NTPs and inhibitor after preincubation of the enzyme and template for 30 min at room temperature. Reactions proceeded for 2 h at room temperature and were quenched with 0.5 M EDTA. Product formation was determined by DE-81 filter binding (Whatman) as described previously (13) . The inhibitor concentration at which the enzyme catalyzed rate is reduced by half (IC 50 ) was determined by fitting the relative rate data to the Hill equation,
where v i is the reaction velocity in the presence of inhibitor, v 0 is the reaction velocity in the absence of inhibitor, and n is the Hill coefficient. Data fitting was carried out using Kaleidagraph (Synergy Software). The incorporation and extension of 2Ј-C-Me triphosphates were analyzed in reactions measuring incorporation of cold nucleoside analogs into 5Ј-32 P end-labeled oligoribonucleotide templates. Templates were designed to fold into a hairpin structure with the first available template base as a U followed by an A (Fig. 2A) or C followed by A (Fig. 2B) . Reaction conditions for incorporation and extension of 2Ј-C-Me analogs were as described previously (10) .
Replicase Assay-HCV replication complexes were isolated by differential centrifugation from HB1 or 2Ј-C-Me-A-resistant HB1 cells and assayed as described previously (14) in the presence or absence of 2Ј-C-Me triphosphates. Reaction products were separated on denaturing 1% agarose gels and quantitated by phosphorimaging analysis.
Synergism Studies-HBI10A cells (11) were plated 16 h before drug addition. The two drugs to be combined were diluted serially 2-fold in 100% Me 2 SO, such that the IC 50 falls in the middle of 8 point titrations, and were added to cells at a final 1% Me 2 SO concentration. The compounds were tested separately in replicate or in combination by adding one set of compound dilutions horizontally and the second vertically to the wells from the highest to lowest concentration such that the titra- 
TABLE II Characterization of Huh7 cells harboring HCV replicons resistant to 2Ј-C-Me-A (HBI-R)
Compound b Determined in in vitro assay using replicase isolated from indicated replicon cells as described under ''Experimental Procedures.'' c In vitro NS5B assay using a heteromeric template.
tions overlap. The plates were analyzed using a 96-well in situ RNase protection assay format at 48 h post-drug addition. The percentage inhibition was determined in comparison with untreated control cells, and the data were analyzed using a nonlinear regression model (15) to determine whether the combination is additive, synergistic, or antagonistic. Additivity curves were predicted from the data for each compound alone using the similar or joint action model, fitted by including a parameter for additivity ( ϭ 0) or non-additivity ( Ͼ 0). Combined data that fall above the curves indicate synergism ( Ͼ 0) and below the curve ( Ͻ 0) indicate antagonism. Antiviral Activity with Additional Viruses-Non-HCV antiviral assays were performed at the Utah State University Institute for Antiviral Research under the direction of Dr. Robert Sidwell. The EC 50 and CC 50 values of 2Ј-C-Me-A and 2Ј-C-methyl-guanosine (2Ј-C-Me-G) were determined in cell culture antiviral assays against the following 13 viruses (strain): West Nile (New York isolate), dengue type 2 (New Guinea), yellow fever (17D), rhino type 2 (HGP), rhino type 14 (1059), polio 3 (WM-3), western equine encephalitis (California), Venezuelan equine encephalitis (Trinidad), respiratory syncytial (A2), measles (Chicago), human cytomegalovirus (AD-169), herpes type 1 (McCrae), and herpes type 2 (E194). The preceding assays, with the exception of human cytomegalovirus, are described by Sidwell and Huffman (16) and were used in the reports of in vitro antiviral activity of ribavirin (17, 18) . Once cellular monolayers were established, compound dilutions were added corresponding to 4-point or 7-point titrations followed by the addition of virus after ϳ5 min. Toxicity measurements were determined from cells treated with compound without the addition of virus. Cells were incubated with compound and virus until viral controls had adequate cytopathic effect (CPE) (Ն3 days for all viruses) for measurement. The cells were then microscopically examined for both virusinduced CPE and compound related toxicity. The EC 50 and CC 50 values were calculated by regression analysis of the viral CPE data and toxicity control data. A Neutral Red Assay confirmation of the viral CPE results, as described previously (19) , was performed, and the results are listed in Table IV . The human cytomegalovirus protocol is based on a plaque reduction assay described previously (20, 21) . Bovine diarrhea virus replication was quantitated using an in situ RNase protection assay as described previously (14) .
Pharmacokinetic Studies-Compounds were formulated in saline at 1.0 mg/ml and dosed intravenously at 1.0 mg/kg and orally at 2.0 mg/kg in male Sprague-Dawley rats. Blood was collected in heparinized tubes and spun down in a centrifuge, and the plasma was decanted and frozen until analyzed. Plasma samples (50 l) were pretreated via protein precipitation with acetonitrile. Samples were analyzed using a PerkinElmer high pressure liquid chromatography with a 2 ϫ 50-mm Zorbax SB-CN (Mac-Mod Analytical, Chadds Ford, PA) column connected to a Sciex API 3000 (Toronto, Canada) triple quadrupole mass spectrometer equipped with a turbo ion spray source operated in the positive selected reaction monitoring mode. Data were collected and analyzed using Sciex Analyst 1.0 Software. Pharmacokinetic calculations were performed using Watson version 6.02.0.02 for Windows (Pharmaceutical Software Systems, Inc., Wayne, PA). Plasma clearance and elimination half-life were calculated using data from the intravenously dosed subjects. Oral bioavailability was calculated as the area under the curve (AUC) from the oral dose divided by the AUC from the intravenous dose times 100.
Construction of NS5B Model with Bound Inhibitor-The active sites of the HCV NS5B polymerase (Protein Data Bank code 1GX6; Ref. 6 ) and the bacteriophage ⌽6 RNA-dependent RNA polymerase (Protein Data Bank code 1HI0; Ref. 23) were overlaid, and the initiation complex from the latter was carried along and copied into the NS5B active site. Next, the side chain of Arg-158 in NS5B was manually repositioned to bind the NTP ␤-phosphate as observed in the ⌽6 crystal structure. A 12-Å zone of NS5B around the active site was extracted and divided into the following subzones: incoming NTP, primer, template, metal ions, residues within 4 Å of the NTP, and residues further than 4 Å from the NTP. The structure was optimized by iterative cycles of minimization of the complex to low gradient using different restraints on the various zones followed by decreasing restraints until a low energy structure was obtained without excessive motion relative to the initial complex. Minimization was performed in MacroModel (24) using the molecular mechanics force field and a dielectric constant of 50. The weakest constraints, initially 5 kcal/mol⅐Å 2 , were placed on the template; medium strength constraints, 20 kcal/mol⅐Å 2 , were placed on the NTP, primer, and side chains of nearby residues; and the strongest constraints, 400 kcal/mol⅐Å 2 , were placed on the metal ions, distant residues, and backbone atoms of nearby residues. Base-pairing was also enforced with high strength constraints. Following each minimization cycle, the restraint force constants were multiplied by 0.75. The minimization was stopped after 20 cycles.
RESULTS
Cell Culture HCV Antiviral Activity of 2Ј-C-Methyl Nucleosides Is Directed against the Viral Polymerase-To further explore the contribution of the 2Ј-methyl-ribose in NS5B inhibition, 2Ј-C-Me-G was synthesized and characterized. The activity of 2Ј-C-Me-A and 2Ј-C-Me-G on viral replication was determined in Huh7 cells using the HCV replicon system (25, 26) , and their activity as triphosphates against purified NS5B was also determined in parallel experiments. Viral replication was quantified using an in situ ribonuclease protection assay that directly measures viral RNA. Both 2Ј-C-Me-substituted compounds and 2Ј-O-Me-C inhibited NS5B polymerase activity and HCV replication without overt toxicity to replicon cells in a 24-h assay ( Table I ), indicating that the 2Ј-Me modification confers antiviral activity irrespective of the base. HCV replication was inhibited to a similar extent following incubation of a Kinetic parameters were determined as described under "Experimental Procedures," with the heteromeric RNA template Dcoh (22) .   FIG. 1 . A, comparative activity of parental and S282T replicons. Replicon RNA was transfected into highly permissive MR2 cells, and replication activity was measure by quantitation of blue light emission as described previously (12) . Two independent experiments are shown. B, sensitivity of parental and S282T replicons to 2Ј-C-methyl nucleosides. MR2 cells transfected with parental and S282T replicon RNA were incubated with different compounds as indicated, and replication activity was measured after 48 h of incubation with compound. 2Ј-C-Me-A and 2Ј-C-Me-G were added at ϳ10ϫ IC 50 , and compound A was added at 40ϫ IC 50 . DMSO, dimethyl sulfoxide.
replicon
Importantly, quantitation of nucleoside triphosphate levels in Huh7 cells revealed a correlation between nucleoside phosphorylation and inhibition of HCV replication (Table I) .
Selection and Characterization of Resistant Mutants-To investigate whether the antiviral activity exhibited by these compounds was due to direct inhibition of the viral polymerase, HCV replicons resistant to 2Ј-C-Me nucleosides were selected and characterized. Following incubation of replicon harboring cells with G418 and escalating concentrations of 2Ј-C-Me-A, several drug-resistant cell clones were isolated and four were further characterized. Resistant cell clones were phenotypically similar to parental cells, as they exhibited identical growth rates and had comparable levels of both viral RNA and protein (data not shown). More importantly, these clones exhibited reduced susceptibility to 2Ј-C-Me-A, with IC 50 s at least four times higher than that of parental cells (Table II) . The sensitivity of a representative cell clone to various inhibitors was characterized in detail and revealed cross-resistance to 2Ј-C-Me-G but not to the nucleoside 2Ј-O-Me-C, suggesting that resistance is directed against the 2ЈC-Me-ribose (Table II) .
To address the formal possibility that a cellular mechanism could be responsible for the resistant phenotype of 2Ј-C-Me-Aresistant cell clones, viral replication complexes were isolated from parental and 2Ј-C-Me-A-resistant Huh7 cells and their sensitivity to 2Ј-C-Me triphosphates assayed as described previously (14) . As shown in Table II , the sensitivity of HCV replication complexes isolated from resistant cells to 2Ј-C-Me-ATP and 2Ј-C-Me-GTP was markedly reduced compared with replicase complexes isolated from parental cells, indicating resistance maps to a component of the viral replication complex. Sequence analyses indicated that replicons isolated from resistant clones contained several mutations that were not present in parental cells. However, the only mutation common among all resistant clones was the substitution of serine 282 of NS5B with threonine (S282T). Therefore, the S282T substitution was introduced into a cell culture adapted replicon vector expressing ␤-lactamase, and replication activity was measured using transient replication assays. Replicon RNA was transfected into highly permissive Huh7 cells, and replication was measured as previously described (12) . The S282T replicon was debilitated for transient replication, achieving only 8 -17% of the activity of the control (Fig. 1A) . Both control and S282T replicons were cultured in the presence of compound equivalent to 10 times the EC 50 for 2Ј-C-Me-A, 2Ј-C-Me-G, and a control non-nucleoside NS5B inhibitor (compound A). As shown in Fig.  1B , the wild type replicon was inhibited by all three compounds, however, the S282T replicon was resistant to both 2Ј-C-Me-substituted nucleosides while remaining sensitive to a non-nucleoside NS5B inhibitor. The characterization of compound A will be described elsewhere. Similar analyses with S282T NS5B also showed cross-resistance to 2Ј-C-Me-substituted inhibitors. As observed with the resistant replicons, 2Ј-O-Me-C had similar efficacy against WT and S282T NS5B (Table II) . Collectively, these results demonstrate that the NS5B S282T mutation is sufficient to confer antiviral resistance to 2Ј-C-Me-modified nucleosides and suggest that S282T-associated resistance is directed to the 2Ј-C-Me-ribose.
Mechanism of Antiviral Resistance to 2Ј-C-Me Nucleosides-
The properties of S282T NS5B were further characterized to better understand the mechanisms involved in S282T-mediated resistance to 2Ј-C-Me-substituted nucleosides. Steadystate kinetic parameters were determined for WT and S282T enzymes (Table III) . In agreement with the attenuated phenotype of replicons engineered to contain the S282T mutation, the catalytic efficiency (k cat /K m ) of S282T NS5B (0.042 M Ϫ1 min Ϫ1 ) was reduced by 11-fold compared with the WT enzyme (0.46 M Ϫ1 min Ϫ1 ). The IC 50 values for inhibition of S282T NS5B by 2Ј-C-Me-ATP and 2Ј-C-Me-GTP were 84 and 20 M, respectively, representing 60-and 100-fold increases compared with the WT enzyme (Table II) . In contrast, the IC 50 for inhibition by 2Ј-O-Me-CTP was only 4-fold higher for the mutant enzyme, demonstrating that the S282T mutation confers resistance to the 2Ј-C-Me-ribose modification. As previously shown for the inhibition of WT NS5B by 2Ј-C-Me-ATP or 2Ј-OMe-CTP (10), inhibition of WT and S282T NS5B by 2Ј-C-Me-ATP and 2Ј-C-Me-GTP and 2Ј-O-Me-CTP was determined to be competitive versus the corresponding NTP, and the K i values showed 115-, 240-, and 7-fold increases for the mutant enzyme, respectively (data not shown). Gel-based incorporation assays were performed to investigate the basis for resistance. The results shown in Fig. 2A indicate that the mutant enzyme was able to extend 2Ј-C-Me-AMP (and to a lesser extent 2Ј-C-Me-GMP) terminated templates by addition of the next correct nucleotide to a greater degree than the WT enzyme (Fig 2) . Together, these results indicate that the S282T mutation confers resistance in the enzyme to 2Ј-C-Me-substituted nucleotides by decreasing the affinity for the inhibitory species, as reflected in the increase in IC 50 and K i . Upon incorporation of   FIG. 2 . Phosphorimages of the incorporation/extension of nucleotide analogs with WT and S282T NS5B. A, reactions included 600 nM 5Ј-32 P end-labeled RNA hairpin 68N with 1 M NS5B⌬55 purified as described previously (13) and nucleoside triphosphates and/or nucleoside triphosphate analogs as shown in the figure. The sequence of template 68N is shown as a hairpin structure. B, reactions were as described in A except that RNA hairpin GU was used instead of hairpin 68N, and reactions received GTP instead of ATP.
the nucleotide analog, the S282T mutant also shows an increased ability to extend the analog-terminated primer relative to WT, an ability that may additionally contribute to resistance.
2Ј-Modified Nucleosides Exhibit Broad Spectrum Antiviral Activity That Is Specific for Viruses Encoding Phylogenetically
Related RdRps-Sequence analyses demonstrate that RdRps are highly conserved among positive strand RNA viruses (27) , suggesting that 2Ј-C-Me-substituted nucleoside analogs might possess antiviral activity against other RNA viruses. To investigate the breadth of antiviral activity of these compounds, the activity of 2Ј-C-Me-A and 2Ј-C-Me-G was evaluated against a broad panel of RNA and DNA viruses (Table IV) . The 2Ј-C-Mesubstituted nucleosides exhibited antiviral activity against several members of the Flaviviridae and Picornaviridae virus families, but antiviral activity was not observed against either negative strand RNA viruses or DNA viruses. Although some cytotoxicity was observed with 2Ј-C-Me-A at higher concentrations, this compound exhibited a favorable selectivity index (CC 50 /EC 50 ) against Flaviviridae and Picornaviridae replication, suggesting a direct antiviral component of its inhibition (Table  IV) . Thus the broad antiviral activity of these compounds against FIG. 3 . Combined effect of nucleosides upon HCV replication. Plot of nucleoside inhibition in replicon cells at the indicated levels. The inhibitory curves for the data observed in the absence and presence of the added compound and the predicted additive curve for the combined compounds are shown. The estimated non-additivity parameter, , and the error of the indicated combinations of compounds predicted by the nonlinear regression modeling method are shown (15) . A, plots with the symbols q and OE represent observed activity curves for 2Ј-C-Me-G (0.125-4 M) without Hu-IFN-␣ and with 37 IU/ml Hu-IFN-␣, respectively. The solid line depicts the predicted additivity curve for the combination of 2Ј-C-Me-G (0.125-4 M) with 37 IU/ml Hu-IFN-␣. B, plots with the symbols q and OE represent observed activity curves for of 2Ј-C-Me-A (0.015-0.5 M) without 2Ј-C-Me-G and with 4 M 2Ј-C-Me-G, respectively. The solid line depicts the predicted additivity curve for the combination of 2Ј-C-Me-A (0.015-0.5 M) with 4 M 2Ј-C-Me-G. b Antiviral assays performed were at Utah State University as described under "Experimental Procedures" (n ϭ 1 or 2, average value reported). c Antiviral activity was obtained from CC 50 /EC 50 .
TABLE IV Antiviral activity of 2Ј-C-methyl-adenosine and 2Ј-C-methyl-guanosine against viruses encoding phylogenetically related polymerases
viruses encoding phylogenetically related RdRps is unambiguous. Remarkably, 2Ј-C-Me-G exhibited no discernible cytotoxic effect in any of the cell lines tested. The cellular toxicity associated with 2Ј-C-Me-A becomes more pronounced with longer incubation times and might be because of interference with one or more of the many biological processes regulated by adenine and its derivatives. Therefore, 2Ј-C-Me-G was used to further characterize this compound class.
Synergistic Inhibition of HCV Replication by 2Ј-C-Me
Nucleosides and Interferon-␣-The ability of novel HCV chemotherapeutic agents to act synergistically with IFN-␣ and/or ribavirin to inhibit HCV replication might increase the clinical utility of new drug candidates. To explore this possibility, the combined effect of 2Ј-C-Me-G with human interferon-␣ (IFN-2␣) or 2Ј-CMe-A was tested in a 48-h HCV replicon assay. The resulting data were fit using a nonlinear regression model (15) to assess the statistical significance of the observed combined effect relative to the predicted additive effect of the two compounds (Fig.  3) . The antiviral activity of 2Ј-C-Me-G is significantly increased when combined with IFN-2␣, and the observed inhibition falls above the additivity curve predicted for the two compounds, indicating that this combination is statistically synergistic ( ϭ 1.66, p Ͻ 0.001). Interestingly, identical analyses revealed a lesser degree of synergism when 2Ј-C-Me-G and 2Ј-C-Me-A were combined ( ϭ 0.7 and p Ͻ 0.001).
Pharmacokinetic Parameters in Rats-To further assess the potential clinical utility of this inhibitor class, the pharmacokinetic properties of 2Ј-C-Me-G were compared with 3TC, a nucleoside inhibitor used to treat both hepatitis B and HIV in humans (Fig. 4) . The oral bioavailability of 2Ј-C-Me-G and 3TC was 82 and 55%, respectively in rats. In addition, 2Ј-C-Me-G exhibited low plasma clearance (13 ml/min/kg) suggesting that its greater bioavailability may be because of a reduced first pass effect as compared with 3TC, which has a plasma clearance of 26 ml/min/kg. The elimination half-life of 2Ј-C-Me-G (2 h) is twice that of 3TC and together with its greater bioavailability results in a dose-normalized exposure of 3.7 M⅐h⅐kg/mg versus 1.5 M⅐h⅐kg/mg for 3TC. After rats were dosed oral with 2Ј-C-Me-A, plasma levels of the compound were undetectable, suggesting little or no bioavailability and/or rapid metabolism of the compound. These rodent pharmacokinetic data suggest that 2Ј-C-Me-G might have clinical utility in the treatment of HCV and flavivirus infection.
DISCUSSION
The studies presented herein demonstrate that 2Ј-C-Memodified nucleosides act as direct inhibitors of HCV NS5B both in vitro and in vivo, thus validating this compound class as bona fide HCV antiviral agents. A single mutation within the RdRp enzyme active site, S282T, is sufficient to confer resistance to 2Ј-C-Me-A and the corresponding guanosine ribonucle- Fig. 5 . 2Ј-C-Me-ATP, in orange, has now moved to the primer position and orients its 2Ј-C-Me group toward the next incoming NTP, shown in green. The additional methyl group clashes sterically with the NTP as indicated by the transparent spheres at the van der Waals distance of the carbon atom of the 2Ј-C-Me-ATP methyl group and the ribose oxygen and C1Ј atoms of the NTP. This model was derived as described under "Experimental Procedures" by importing the ⌽6 initiation complex (23) from Protein Data Bank code 1HI0 and adapting it to the NS5B active site by constrained minimization.
oside. That resistance is conferred to ribonucleosides differing only in the base further suggests that resistance is directed toward the 2Ј-C-Me-ribose moiety. This conclusion is further supported by biochemical evidence that replicon cells resistant to 2Ј-C-Me-substituted nucleosides remain sensitive to the related analog 2Ј-O-Me-C (Table II) .
To gain further insight into the mechanism of chain termination and resistance, a model of the NS5B initiation complex was generated from the NS5B crystal structure and the ⌽6 RdRp initiation complex crystal structure (6, 23) . The model places the 2Ј-C-methyl group in close proximity to Ser-282 prior to the NTP being added to the primer (Fig. 5) . Although the effect of the S282T mutation on the NS5B structure is unknown, this proximity is consistent with the S282T mutation decreasing the affinity for 2Ј-C-Me-substituted nucleosides. Furthermore, this model also suggests that incorporation of the 2Ј-C-Me-modified nucleotide in the primer position may result in steric hindrance between the methyl group and the ribose of the incoming NTP, providing a possible mechanism by which 2Ј-C-Me analogs could effect chain termination (Fig. 6) . The ability of S282T NS5B, but not WT NS5B, to elongate 2Ј-C-Meprimed nucleosides is not explained by the model, and it may depend on the influence of the S282T mutation on the NS5B structure.
Sequence analyses across different HCV genotypes demonstrate a high level of conservation in the NS5B active site including the predicted ribonucleotide substrate binding site (27) , suggesting that the ribonucleoside inhibitors described here might be broadly active against all clinically relevant HCV genotypes. In agreement with this hypothesis, antiviral screening against a panel of RNA and DNA viruses revealed antiviral activity by these nucleoside analogs against members of the Flaviviridae and Picornaviridae virus families (Table  IV) . A high degree of conservation is exhibited at Ser-282 across different genotypes, consistent with the finding that replicons into which the S282T mutation is introduced are attenuated in transient replication assays (Fig. 1A) . However, this is in contrast with the observation that resistant cell lines selected with 10-fold the IC 50 concentration of 2Ј-C-Me-A have growth rates and levels of replicon RNA similar to parental replicon cells (not shown). Possible explanations to this apparent paradox include the existence of yet unidentified compensatory mutations in replicons selected for resistance or the possibility that the effect of the S282T mutation on viral replication may be context-dependent and variable among different isolates.
Selectivity studies showed that 2Ј-C-Me-substituted nucleoside triphosphates do not inhibit human DNA polymerases nor DNA-dependent RNA polymerases (Ref. 10 and data not shown) indicating that the 2Ј-C-Me-ribose modification selectively converts natural nucleosides into inhibitors of RdRps from HCV and related positive strand RNA viruses. The specificity of 2Ј-C-Me-substituted analogs for inhibition of viral RdRps suggests that compounds with a favorable pharmacological profile such as 2Ј-C-Me-G represent attractive candidate antiviral agents against HCV and other important human pathogens including West African Nile, yellow fever, and dengue viruses.
